FILE PHOTO: The Merck logo is seen on a sign at the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid
MILAN/FRANKFURT/NEW YORK (Reuters) - As COVID-19 infections rise, people seeking to avoid one lung disease compounding another are queuing up to get inoculated against bacterial pneumonia, causing shortages of a Merck & Co vaccine in parts of Europe.
Demand for Merck's Pneumovax 23, which is used to prevent pneumococcal lung infections, has hit record highs across the world, the company said.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
